Format

Send to

Choose Destination
Nat Rev Dis Primers. 2015 May 14;1:15010. doi: 10.1038/nrdp.2015.10.

Cystic fibrosis.

Author information

1
Division of Respiratory Medicine, Department of Paediatrics, The Hospital for Sick Children and University of Toronto, 555 University Avenue, Toronto M5G 1X8, Canada.
2
Department of Thoracic Medicine, Queensland Children's Medical Research Institute, Brisbane, Queensland, Australia.
3
Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
4
Division of Pulmonary and Critical Care Medicine, University of Washington Medical Center, Seattle, Washington, USA.
5
Department of Psychology, University of Miami, Miami, Florida, USA.
6
Paediatrics Section, Imperial College, Paediatric Respirology, National Heart and Lung Institute, and the Royal Brompton Harefield NHS Foundation Trust, London, UK.

Abstract

Cystic fibrosis is an autosomal recessive, monogenetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The gene defect was first described 25 years ago and much progress has been made since then in our understanding of how CFTR mutations cause disease and how this can be addressed therapeutically. CFTR is a transmembrane protein that transports ions across the surface of epithelial cells. CFTR dysfunction affects many organs; however, lung disease is responsible for the vast majority of morbidity and mortality in patients with cystic fibrosis. Prenatal diagnostics, newborn screening and new treatment algorithms are changing the incidence and the prevalence of the disease. Until recently, the standard of care in cystic fibrosis treatment focused on preventing and treating complications of the disease; now, novel treatment strategies directly targeting the ion channel abnormality are becoming available and it will be important to evaluate how these treatments affect disease progression and the quality of life of patients. In this Primer, we summarize the current knowledge, and provide an outlook on how cystic fibrosis clinical care and research will be affected by new knowledge and therapeutic options in the near future. For an illustrated summary of this Primer, visit: http://go.nature.com/4VrefN.

PMID:
27189798
DOI:
10.1038/nrdp.2015.10
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center